Blake Vanderhyde

Smiling man with ocean backdrop during sunset.

Consultant, AI Founder, Lawyer

Blake Vanderhyde, Esq.

Former Advisor to Arobella Medical, LLC

Blake Vanderhyde is a Minnesota attorney and the founder of Vanderhyde Law, a plaintiff practice focused on mass tort litigation. He is also the founder of Vanderhyde Consulting and the co-founder of A4A, Inc., a company building artificial intelligence tools for plaintiff law firms.

From 2020 to 2025, Blake worked as a consultant and public health advocate on antimicrobial resistance, in collaboration with former U.S. Senator Rudy Boschwitz, medical device entrepreneur Michael Afremov, physicist and inventor Dr. Eliaz Babaev, and Arobella Medical, LLC.

Blake graduated summa cum laude from Saint Cloud State University and earned his law degree from William Mitchell College of Law, where he served on the Law Review. He is licensed to practice in state and federal courts in Minnesota and has been recognized by Super Lawyers, Minnesota Law and Politics, and Who's Who.

This website is provided solely to stimulate open scientific discussion and paradigm thinking on antimicrobial resistance (AMR), a top-10 global health threat according to the World Health Organization. This website is not medical advice, device promotion, or an endorsement of any product, person or use. All references to specific technologies are illustrative and hypothetical only. Readers (including clinicians) must not use any device mentioned in the studies for uncleared indications.

The website discusses bactericidal resonance as purely a physics-based hypothesis for research purposes. Clinicians and facilities must not utilize any low-frequency ultrasound device, for the purpose of destroying bacteria or treating infections. Such use is not FDA-cleared, and its safety for these specific indications has not been established in human clinical trials.

This website is provided for informational and educational purposes only. It does not constitute an offer to sell securities, a solicitation of interest in any securities offering, medical advice, or investment advice. The author is not a medical doctor or a registered investment advisor. Certain statements in this article may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to differ materially, including but not limited to: failure of in vivo scientific validation, adverse FDA classification or pathway decisions, inability to secure development financing, unforeseen competitive developments, regulatory changes, and loss of key inventor knowledge. The technology discussed is currently FDA-cleared only for wound cleansing and debridement; the antimicrobial applications discussed here are purely investigational and are not FDA-cleared for antimicrobial indications. Readers are cautioned not to use any medical device for indications not cleared by the FDA. As of the date of publication, no legal entity has been formed or identified for purposes of any securities offering related to this technology. The author is not currently seeking, and will not accept, any inquiries regarding investment or financial participation. Any future financing, if any, would be conducted only through formal offering materials and in compliance with applicable federal and state securities laws. Do not rely on this content for investment, legal, or medical decisions.

Articles

Blake Vanderhyde

Consultant, AI Founder, Lawyer

This website uses cookies.